NCT03465683 Transmission of ESBL-producing Enterobacteriaceae
| NCT ID | NCT03465683 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Hospital Acquired Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2017-03-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2017-03-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this research project is to investigate the transmission of ESBL-producing Enterobacteriaceae on both, the level of bacterial strains and mobile genetic elements, and to determine the source of hospital-acquired infections.
Eligibility Criteria
Inclusion Criteria: * aged above 1 year * proven ESBL-PE carriage from any specimens obtained by routine clinical practice out and inpatients from University Hospital Basle from January 1st until December 31st 2019 Exclusion Criteria: * not meeting inclusion criteria
Contact & Investigator
Sarah Tschudin-Sutter, PD MD
PRINCIPAL INVESTIGATOR
Division of Infectious Disease and Hopital Epidemiology, University Hospital Basle
Frequently Asked Questions
Who can join the NCT03465683 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, studying Hospital Acquired Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03465683 currently recruiting?
Yes, NCT03465683 is actively recruiting participants. Contact the research team at sarah.tschudin@usb.ch for enrollment information.
Where is the NCT03465683 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT03465683 clinical trial?
NCT03465683 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Sarah Tschudin-Sutter, PD MD at Division of Infectious Disease and Hopital Epidemiology, University Hospital Basle. The trial plans to enroll 2,000 participants.